Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2021.113244
Abstract: Cyclin-dependent kinases (CDKs) are a family of Ser/Thr kinases involved in cell cycle and transcriptional regulation. CDK9 regulates transcriptional elongation and this unique property has made it a potential target for several diseases. Due to… read more here.
Keywords: cdk9 inhibitors; cdk9; structure based; selective cdk9 ... See more keywords
Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Oncology"
DOI: 10.1159/000526978
Abstract: Purpose: Composite cyclin-dependent kinase (CDK) inhibition has shown potential as a treatment for hepatocellular carcinoma (HCC) in preclinical studies. We tested whether the specific inhibition of CDK9 was effective against HCC. Methods: The effects of… read more here.
Keywords: inhibition; hcc cells; cdk9 inhibitors; hcc ... See more keywords
CDK9: Therapeutic perspective in HCC therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Current cancer drug targets"
DOI: 10.2174/1568009620666200212124357
Abstract: CDK9 is an important cell-cycle control enzyme essential in transcription, elongation, and mRNA maturation. Overexpression of CDK9 has been reported in several diseases, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and malignant melanoma. Recent research… read more here.
Keywords: therapeutic perspective; hcc; cdk9 inhibitors; cdk9 therapeutic ... See more keywords
EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Haematologica"
DOI: 10.3324/haematol.2019.222935
Abstract: Aberrant expression of CDK9/cyclin T1 has been found in diffuse large B-cell lymphoma (DLBCL), and suggests that CDK9 is a potential therapeutic target for DLBCL. Here, we firstly demonstrated that CDKI-73, a novel cyclin-dependent kinases… read more here.
Keywords: cdk9 inhibitors; ezh2 inhibitors; cdk9; trimethylation h3k27 ... See more keywords